Streamlining Genetic Testing Prior Authorization with Da Vinci PAS

The Challenge of Genetic Testing Prior Authorization

Genetic testing prior authorizations are among the most complex, driven by evolving clinical guidelines and frequent routing to third-party benefit managers (RBMs). Manual processes involving payer-specific portals and fax submissions lead to significant delays and high administrative overhead, impacting patient care timelines and staff productivity. This complexity is particularly acute for high-volume categories like hereditary cancer panels, prenatal genetic testing, and pharmacogenomics.

Introducing Da Vinci PAS for Genetic Testing Workflows

The HL7 Da Vinci Project's Prior Authorization Support (PAS) Implementation Guide, built on HL7 FHIR R4, offers a standardized pathway for prior authorization. For genetic testing, Da Vinci PAS enables the electronic exchange of structured clinical documentation and authorization requests directly between providers and payers, moving beyond the limitations of legacy systems and unstructured attachments.

Current State: Manual Genetic Testing PA Workflow

• **Payer-Specific Portals:** Submitting genetic testing PAs through disparate portals like Availity, UHCprovider.com, or CignaforHCP, each requiring unique login and data entry.
• **Unstructured Clinical Documentation:** Attaching clinical notes, family histories, and genetic test results as PDFs or scanned documents, often via the X12 275 supplemental information transaction, hindering automated review.
• **Fax Fallback:** Relying on fax for submissions or additional documentation requests when electronic channels are unavailable or insufficient.
• **Inconsistent Response Handling:** Manually tracking approval, denial, or pending statuses, which vary in format and codes across different payers and RBMs like eviCore and Avalon.

Klivira's Automated Genetic Testing PA with Da Vinci PAS

Klivira's platform implements Da Vinci PAS conformance to automate genetic testing prior authorizations end-to-end. At order entry, Da Vinci CRD (Coverage Requirements Discovery) identifies PA requirements for specific genetic tests. Where supported by the payer, Da Vinci DTR (Documentation Templates and Rules) guides the assembly of structured clinical data, populating questionnaires directly from EMR FHIR resources. The complete request is then submitted via the standardized FHIR $submit operation.

Compliance and Future-Proofing with CMS-0057-F

The Centers for Medicare & Medicaid Services (CMS) rule CMS-0057-F mandates that impacted payers implement a Prior Authorization API by January 1, 2027, aligning with Da Vinci PAS conformance. This regulatory push ensures that a growing number of payers, including those handling Medicare Advantage, Medicaid managed-care, and CHIP managed-care plans, will support FHIR-based PA for genetic testing. Klivira tracks payer conformance and facilitates seamless transitions from test environments to production endpoints.

Key Benefits for Genetic Testing PA with Klivira's Da Vinci PAS

• **Standardized Submissions:** Eliminates per-payer custom integrations, using a uniform FHIR operation interface for all genetic test authorizations.
• **Structured Clinical Data:** Replaces unstructured PDF attachments with DTR-driven questionnaires and FHIR resources, enabling faster payer-side automated review for genetic test results.
• **Consistent Response Handling:** Standardizes `ClaimResponse` parsing into a single workflow state taxonomy, regardless of the payer or RBM.
• **Reduced Administrative Burden:** Automates status tracking via inquiry operations or push notifications, reducing manual follow-up for pending genetic testing authorizations.
• **EMR Integration:** Writes the `ClaimResponse` decision, authorization number, and conditions back to the EMR's order record for genetic tests, ensuring a unified patient record.

Klivira's Comprehensive Approach to Genetic Testing PA

Klivira's platform prioritizes Da Vinci PAS for payers in production conformance. For payers not yet supporting PAS, Klivira intelligently routes genetic testing prior authorizations via traditional X12 278 transactions (often with X12 275 for attachments) or through existing payer portals. This hybrid approach ensures continuous prior authorization coverage across all payers while preparing your organization for the industry's shift to FHIR-based standards, including those impacting high-cost genetic services.